US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
OpenAI Nears Astra AI Model Launch With Safety Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
OpenAI Rejects Apple Trade Secret Theft Claims 
Add as a preferred source on Google
TUSTIN, Calif., March 06, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at the 30th Annual ROTH Conference. The conference is being held March 11-14, 2018 at the Ritz-Carlton Laguna Niguel in Dana Point, CA.
Details of this presentation are as follows:
- 30th Annual ROTH Conference
Time/Date: 2:00 p.m. PT on Tuesday, March 13, 2018
Location: Ritz-Carlton Laguna Niguel, Dana Point, CA
Room: Yellow Salon 6
Avid’s presentation at the ROTH conference will be webcast live and available for replay at: http://ir.avidbio.com/events.cfm.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
